RecruitingPhase 1psilocybin

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

Sponsored by Portland VA Research Foundation, Inc

NCT ID
NCT04982796
Target Enrollment
30 participants
Start Date
2022-07-07
Est. Completion
2026-04-30

About This Study

This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder.

Conditions Studied

Amphetamine-Related Disorders

Interventions

  • Psilocybin
  • Treatment-as-usual

Eligibility

Age:25 Years - 65 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* United States military Veteran
* Moderate to severe methamphetamine use disorder using the DSM-V diagnostic criteria
* Desire to cease or reduce methamphetamine use

Exclusion Criteria:

* Have uncontrolled hypertension or clinically significant cardiovascular disease
* History of seizure disorder in adulthood
* CNS metastases or symptomatic central nervous system (CNS) infection
* Poorly controlled diabetes mellitus
* Taking certain medications that may interact with psilocybin
* History of any primary persistent psychotic disorder, including schizophrenia, schizoaffective disorder, bipolar disorder with psychosis, major depressive disorder with psychosis, or schizophreniform disorder
* History of bipolar I disorder
* Current eating disorder with active purging
* History of hallucinogen use disorder
* Pregnant or breast feeding

Study Locations (1)

Portland VA Health Care System
Vancouver, Washington, United States

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

Zoe Gupta, BA
CONTACT
(360) 216-3489Zoe.Gupta@va.gov
Bianca Watt, MSc
CONTACT
(503) 781-1205Bianca.Watt@va.gov
View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder | Huxley